News Archives Archive - Page 28 of 58 - Adverum Biotechnologies

Avalanche Biotechnologies, Inc. Reports Third Quarter 2014 Financial Results

November 12, 2014

MENLO PARK, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Participate in Nomura’s Biotechnology Conference

October 30, 2014

MENLO PARK, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting

October 9, 2014

MENLO PARK, Calif., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Participate in Gene Therapy Panel at the BIO Investor Forum

October 1, 2014

MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies, Inc., Appoints Industry Leader Roman G. Rubio, M.D., as Senior Vice President and Head of Translational Medicine

September 23, 2014

MENLO PARK, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies to Present at the NewsMakers in the Biotech Industry Conference

September 19, 2014

MENLO PARK, Calif., Sept. 19, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies, Inc. Reports Second Quarter 2014 Financial Results

September 11, 2014

MENLO PARK, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic...

Avalanche Biotechnologies Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

August 5, 2014

MENLO PARK, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today...

Avalanche Biotechnologies Prices Initial Public Offering of $102.0 Million of Common Stock

July 31, 2014

MENLO PARK, Calif., July 31, 2014 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc., a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases,...

Avalanche Biotechnologies Announces Appointment of Samuel B. Barone, M.D., as Chief Medical Officer

July 1, 2014

MENLO PARK, Calif., July 1, 2014 -- Avalanche Biotechnologies, Inc., a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the appointment of Samuel B. Barone, M.D. in the...

Archived Press Releases